Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
137.00    -3.00 (-2.14%)
Bid:
137.00
Ask:
144.50
Spread: 7.50 (5.474%)
Market Cap: £107.51m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Trading Statement

16 Jul 2020 07:00

RNS Number : 1439T
Xaar PLC
16 July 2020
 

Xaar plc

 

Trading update 

 

 

Xaar plc ("Xaar", "the Group" or "the Company"), the leading inkjet printing technology, today announces a trading update for the six months ended 30 June 2020.

 

TRADING

 

The Board is pleased to announce that trading for the six months ending 30 June 2020 has been in line with expectations and good progress has been made implementing our strategy. Revenue for the period is expected to be £23.7m, representing a decline of 7% relative to H1 2019 and in line with H2 2019.

 

The Printhead business continues to perform well as changes in the go to market strategy have seen early successes with several new accounts won and customers re-engaging with the business. The restructuring undertaken in the second half of 2019 has left the business well positioned both to deal with the current economic climate but also to deliver a sustainable and strong business in the longer-term.

 

The Product Print Systems business has been impacted by COVID-19 with annuities and machine sales both below our original plan. Despite that, good progress has been made in embedding the new strategy and driving operational performance with revenue slightly increased relative to the first half of 2019.

 

The 3D business has continued to make good progress. Despite minor delays due to lockdown restrictions, product development and testing is progressing well and investment in the go to market strategy is underway.

 

BALANCE SHEET AND LIQUIDITY

 

The Group retains a strong balance sheet and cash position. Cash and cash equivalents at 30 June 2020 were £23.9m with both the Printhead and Product Print Systems business improving their cash balance relative to 31 December 2019. The 3D business continues to be well positioned to fund its development and go to market needs. The Group maintains a strong cash focus and disciplined cost controls.

 

CURRENT TRADING AND OUTLOOK

 

The Group continues to manage operations in response to the constraints caused by COVID-19 with the priority of safeguarding the health and wellbeing of our employees. Despite these constraints, operations have remained effective and efficient.

 

As a result of the continued uncertainty surrounding economic conditions globally, the Board will not be providing guidance at this time. The short-term order book is healthy, and the business is well placed to withstand the difficult trading environment. The Board remains focused on the medium-term strategy to return the business to profitability and growth and will provide more details on our future plans at the half year results in September.

 

John Mills, Chief Executive Officer, commented:

 

"We are pleased with our performance for the first half which is testament to the new strategy we have in place and all of our staff who have managed the business well during a tough period. It has been particularly pleasing to see success in re-engaging with our core customer base whilst also winning new business.

 

Although short-term uncertainty will remain, the changes we have made enable us to be well positioned for the long-term. The fundamentals remain compelling, the market opportunity remains significant and we are excited about future of the business."

 

 

Enquiries:

 

Xaar plc

Ian Tichias, Chief Finance Officer

& Company Secretary

 

+44 (0) 1223 423 663 

John Mills, Chief Executive Officer

 

 

Tulchan Communications

 

 

 

+44 (0) 207 353 4200

James Macey White

Giles Kernick

Hollie Ralston

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKELFFBDLFBBB
Date   Source Headline
3rd Feb 20254:15 pmRNSTotal Voting Rights
22nd Jan 202512:30 pmRNSBlock listing Interim Review
21st Jan 20253:00 pmRNSHolding(s) in Company
15th Jan 20257:00 amRNSTrading update & notification of full year results
15th Jan 20257:00 amRNSAppointment of Chief Financial Officer
11th Dec 202410:30 amRNS2024 Full Year Trading Update
4th Dec 202410:45 amRNSUpdate statement on 2024 AGM voting results
3rd Dec 202410:50 amRNSTotal Voting Rights
20th Nov 20247:00 amRNSBoard changes
1st Nov 202412:00 pmRNSTotal Voting Rights
1st Oct 202411:30 amRNSTotal Voting Rights
18th Sep 20247:00 amRNSInterim Results
2nd Sep 20241:45 pmRNSTotal Voting Rights
2nd Aug 20242:30 pmRNSHolding(s) in Company
1st Aug 202411:15 amRNSTotal Voting Rights
30th Jul 20247:00 amRNSNOTICE OF RESULTS AND UPDATE ON TRADING
3rd Jul 202411:45 amRNSBlock listing Interim Review
2nd Jul 20242:00 pmRNSTotal Voting Rights
28th Jun 202410:00 amRNSDirector Declaration
3rd Jun 20242:45 pmRNSTotal Voting Rights
30th May 202412:00 pmRNSBoard changes
29th May 20241:45 pmRNSResult of AGM
29th May 20249:30 amRNSHolding(s) in Company
21st May 20249:30 amRNSDirector/PDMR Shareholding
20th May 20244:30 pmRNSDirector/PDMR Shareholding
13th May 20249:42 amRNSHolding(s) in Company
1st May 20244:15 pmRNSTotal Voting Rights
30th Apr 20244:30 pmRNSDirector/PDMR Shareholding
22nd Apr 202410:51 amRNSAnnual Financial Report
2nd Apr 202412:00 pmRNSTotal Voting Rights
1st Mar 202410:15 amRNSTotal Voting Rights
26th Feb 20249:00 amRNSHolding(s) in Company
23rd Feb 202410:30 amRNSBoard Change
1st Feb 20241:32 pmRNSTotal Voting Rights
29th Jan 202412:04 pmRNSHolding(s) in Company
12th Jan 20243:15 pmRNSBlock listing Interim Review
12th Jan 20247:00 amRNSNotification of Results & Full year Guidance
8th Jan 202412:36 pmRNSTotal Voting Rights
12th Dec 20239:00 amRNSNotification of Transactions of Directors & PDMRs
11th Dec 20233:00 pmRNSNotification of Transactions of Directors & PDMRs
1st Dec 202311:00 amRNSTotal Voting Rights
1st Dec 202310:00 amRNSDirector Declaration
29th Nov 20237:00 amRNSTrading Update
17th Nov 20234:07 pmRNSHolding(s) in Company
9th Nov 20231:53 pmRNSDirector/PDMR Shareholding
3rd Nov 202310:52 amRNSHolding(s) in Company
1st Nov 20234:03 pmRNSTotal Voting Rights
30th Oct 20237:00 amRNSBoard Changes
2nd Oct 202311:45 amRNSTotal Voting Rights
21st Sep 20233:16 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.